Evidence map›Paper›PMID 34199386›Full record

ArticleCancers2021

Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions.

Antonio Gómez, Miguel L Pato, Luis Bujanda, Núria Sala, Osmel Companioni, Ángel Cosme, Martina Tufano, David J Hanly, Nadia García, José Miguel Sanz-Anquela and 18 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 1 country.

Antonio GómezCancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0001-5308-981X
Miguel L PatoCancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), 08908 Barcelona, Spain.
Luis BujandaDepartment of Gastroenterology, Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco (UPV/EHU), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, 20014 San Sebastián, Spain.
Núria SalaUnit of Nutrition, Environment and Cancer, Institut Català d'Oncología, 08908 Barcelona, Spain.ORCID 0000-0003-3585-7613
Osmel CompanioniUnit of Nutrition, Environment and Cancer, Institut Català d'Oncología, 08908 Barcelona, Spain.
Ángel CosmeDepartment of Gastroenterology, Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco (UPV/EHU), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, 20014 San Sebastián, Spain.
Martina TufanoCancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), 08908 Barcelona, Spain.
David J HanlyCancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), 08908 Barcelona, Spain.
Nadia GarcíaUnit of Nutrition, Environment and Cancer, Institut Català d'Oncología, 08908 Barcelona, Spain.
José Miguel Sanz-AnquelaDepartment of Pathology, Hospital Universitario Príncipe de Asturias, 28805 Alcalá de Henares, Spain.
Javier P GisbertDepartment of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28006 Madrid, Spain.ORCID 0000-0003-2090-3445
Consuelo LópezDepartment of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28006 Madrid, Spain.
José Ignacio ElizaldeDepartment of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS and CIBEREHD, 08036 Barcelona, Spain.
Miriam CuatrecasasDepartment of Pathology, Hospital Clínic de Barcelona, IDIBAPS and CIBEREHD, 08036 Barcelona, Spain.
Victoria AndreuDepartment of Gastroenterology, Hospital de Viladecans, 08840 Barcelona, Spain.
María José PaulesDepartment of Pathology, Hospital Universitari de Bellvitge, 08907 L'Hospitalet de Llobregat, Spain.
María Dolores Martín-ArranzDepartment of Gastroenterology, Hospital Universitario La Paz, Instituto de Investigación Sanitaria La Paz (IdiPaz), 28046 Madrid, Spain.
Luis OrtegaDepartment of Gastroenterology, Hospital Clínico San Carlos, 28040 Madrid, Spain.
Elvira PovesDepartment of Gastroenterology, Hospital Universitario Príncipe de Asturias, 28805 Alcalá de Henares, Spain.
Jesús BarrioDepartment of Gastroenterology, Hospital Universitario Río Hortega, 47012 Valladolid, Spain.ORCID 0000-0001-7087-3921
María Ángeles TorresDepartment of Pathology, Hospital Universitario Río Hortega, 47012 Valladolid, Spain.ORCID 0000-0002-4240-1422
Guillermo MuñozDepartment of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.
Ángel FerrándezDepartment of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.
María José Ramírez-LázaroDepartment of Medicine, Digestive Diseases Service, Institut Universitari Parc Taulí, 08201 Sabadell, Spain.ORCID 0000-0002-7044-6126
Sergio LarioDepartment of Medicine, Digestive Diseases Service, Institut Universitari Parc Taulí, 08201 Sabadell, Spain.ORCID 0000-0001-9294-1585
Carlos A GonzálezUnit of Nutrition, Environment and Cancer, Institut Català d'Oncología, 08908 Barcelona, Spain.
Manel EstellerCancer Epigenetics Group, Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), 08916 Barcelona, Spain.
María BerdascoCancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), 08908 Barcelona, Spain.
Institut d'Investigació Biomédica de Bellvitge · ESCentro de Investigación Biomédica en Red · ESHospital Clínico Universitario Lozano Blesa · ESHospital Universitario de La Princesa · ESHospital Universitario Príncipe de Asturias · ESHospital Universitario Río Hortega · ESInstitut Català d'Oncologia · ESUniversity of the Basque Country · ESBellvitge University Hospital · ESHospital Clínico San Carlos · ESHospital de Viladecans · ESHospital Universitario La Paz · ESInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

H2020 Marie Skłodowska-Curie Actions SEP-210147404Instituto de Salud Carlos III PI10/01089Instituto de Salud Carlos III PI10/01203Instituto de Salud Carlos III PI10/02267
6 · The paper itself

Abstract

To adopt prevention strategies in gastric cancer, it is imperative to develop robust biomarkers with acceptable costs and feasibility in clinical practice to stratified populations according to risk scores. With this aim, we applied an unbiased genome-wide CpG methylation approach to a discovery cohort composed of gastric cancer (

Indexed as

cancer risk predictionCpG methylationHelicobacter pyloriintestinal type of gastric cancerprecursor lesions

Identifiers

PMID34199386
PMCPMC8199626
OpenAlexW3168127545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.